Welcome to LookChem.com Sign In|Join Free

CAS

  • or

106973-37-9

Post Buying Request

106973-37-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

106973-37-9 Usage

General Description

"(3S)-4-Benzyl-5-oxomorpholine-3-carboxylic acid" is a chemical compound which belongs to the class of organic compounds known as morpholine carboxylic acids and derivatives. These are compounds containing a morpholine ring substituted by a carboxylic acid or a derivative thereof. The morpholine ring is a six-membered aliphatic ring comprising four carbon atoms, an oxygen atom, and a nitrogen atom. The specific structure of "(3S)-4-Benzyl-5-oxomorpholine-3-carboxylic acid" includes a benzyl group attached to the 4th carbon of the morpholine ring. Additionally, it has a carboxylic acid group on the 3rd carbon of the ring and an oxygen (in form of a ketone) on the 5th carbon. The "S" indicates the spatial arrangement of the molecule, according to the Cahn-Ingold-Prelog rules for stereochemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 106973-37-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,9,7 and 3 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 106973-37:
(8*1)+(7*0)+(6*6)+(5*9)+(4*7)+(3*3)+(2*3)+(1*7)=139
139 % 10 = 9
So 106973-37-9 is a valid CAS Registry Number.

106973-37-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-4-Benzyl-5-oxomorpholine-3-carboxylic Acid

1.2 Other means of identification

Product number -
Other names (3S)-4-Benzyl-5-oxomorpholine-3-carboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:106973-37-9 SDS

106973-37-9Relevant articles and documents

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

Borsari, Chiara,Rageot, Denise,Dall'Asen, Alix,Bohnacker, Thomas,Melone, Anna,Sele, Alexander M.,Jackson, Eileen,Langlois, Jean-Baptiste,Beaufils, Florent,Hebeisen, Paul,Fabbro, Doriano,Hillmann, Petra,Wymann, Matthias P.

, p. 8609 - 8630 (2019/10/16)

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ~450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

-

Page/Page column 91, (2011/10/05)

The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurolo

SYNTHETIC PROCESS

-

Page/Page column 29-30, (2008/06/13)

The present invention provides a process for preparing compounds of formula (I) ["insert chemical structure here"](I)or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 106973-37-9